ID4010 Axial spondyloarthritis (non-radiographic, active) - bimekizumab and ID4011 Ankylosing spondylitis - bimekizumab have now been combined and will be appraised under ID6245
Status | Discontinued |
Technology type | Medicine |
Decision | Selected |
Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
Process | TA |
ID number | 4010 |
Project Team
Project lead | Michelle Adhémar |
Email enquiries
- If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
18 May 2023 | Discontinued. ID4010 Axial spondyloarthritis (non-radiographic, active) - bimekizumab and ID4011 Ankylosing spondylitis - bimekizumab have now been combined and will be appraised under ID6245 |
03 November 2022 - 01 December 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
03 November 2022 | In progress. Scoping commenced |
26 September 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual